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Significance: Fibrosis-related events play a part in the pathogenesis or failure
of treatment of virtually all the blinding diseases around the world, and also
account for over 40% of all deaths. It is well established that the eye and other
tissues of some group of patients, for example Afro-Caribbean people, scar
worse than others. However, there is a current lack of reliable biomarkers to
stratify the risk of scarring and postsurgical fibrosis in the eye.
Recent Advances: Recent studies using genomics, proteomics, metabolomics,
clinical phenotyping, and high-resolution in vivo imaging techniques have
revealed potential novel biomarkers to identify and stratify patients at risk of
scarring in different fibrotic eye diseases.
Critical Issues: Most of the studies, to date, have been done in animals or small
cohorts of patients and future research is needed to validate these results in large
longitudinal humanstudies.Detailed clinical phenotypingandeffective biobanking
ofpatient tissueswill alsobe critical for futurebiomarker research inocularfibrosis.
Future Directions: The ability to predict the risk of scarring and to tailor the anti-
fibrotic treatment regimen to each individual patient will be an extremely useful
tool clinically to prevent undertreating, or exposing patients to unnecessary
treatments with potential side effects. An exciting future prospect will be to use
new advances in genotyping, namely next-generation whole genome sequencing
like RNA-Seq, to develop a customized gene chip in ocular fibrosis. Successful
translation of future biomarkers to benefit patient carewill also ultimately require
a strongcollaborationbetweenacademics, pharmaceutical, andbiotech companies.
SCOPE AND SIGNIFICANCE
Fibrosis-related events play a
part in most of the blinding diseases
worldwide (Fig. 1)andalso account for
over 40% of all deaths. It is well es-
tablished that the eye tissues of some
group of patients, for example Afro-
Caribbean people, scar worse than
others. However, there is a current
lack of reliable biomarkers to stratify
the risk of scarring and postsurgical
fibrosis in the eye. This review focuses
on the recent advances in genomics,
proteomics, metabolomics, clinical
phenotyping, and high-resolution
in vivo imaging techniques that
might help to identify and stratify
the groups of patients at risk of
scarring in different parts of the eye.
TRANSLATIONAL RELEVANCE
In the next 10 years, the hope is
that new advances in genotyping,
namely next-generationwhole genome
sequencing, and detailed clinical phe-
notyping using modern tissue bio-
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markers and high-resolution in vivo imaging tech-
niques, will help to identify the groups of patients
that would scar more aggressively, and thus help
to develop a more personalized and stratified ap-
proach in antifibrotic ocular therapeutics. Suc-
cessful translation of future biomarkers in ocular
fibrosis will also ultimately require a strong col-
laboration between academics, pharmaceutical,
and biotech companies.
CLINICAL RELEVANCE
There is a large unmet clinical need for new
predictive and mechanistic biomarkers in ocular
fibrosis. Being able to predict patients’ risk of scar-
ring and to tailor the antifibrotic treatment regi-
men to each individual patient will be an extremely
useful tool clinically to prevent undertreating, or
exposing them to unnecessary treatments with po-
tential side effects.Most of the studies, to date, have
been carried out in animals or small cohorts of pa-
tients, and future research is thus needed to vali-
date these results in large longitudinal human
studies. Detailed clinical phenotyping and effective
biobanking of patient tissues will also be critical for
future biomarker research in ocular fibrosis.
DISCUSSION
Tissue genomics
The NEIBank is a project to gather and organize
genomic resources for eye research.1 The NEIBank
includes expressed sequence tag data and sequence-
verified cDNA clones for multiple eye tissues of
several species, web-based access to human eye-
specific serial analysis of gene expression (SAGE)
data through EyeSAGE, and comprehensive an-
notated databases of known human eye disease
genes and candidate disease gene loci.2–5
Glaucoma is the commonest cause of irreversible
blindness in the world and conjunctival fibrosis is
the major determinant of the surgical success after
glaucoma filtration surgery (Fig. 2). Popp et al.
isolated anterior segment tissues (cornea, con-
junctiva, iris) and posterior segment tissues (lens,
retina, sclera) of rabbit eyes, and created two in-
dependent cDNA libraries through the NEIBank
project.6 Usingmicroarray analysis, they found the
expression of 315 genes to be significantly altered
in the rabbit conjunctiva and Tenon’s capsule after
glaucoma filtration surgery, and these genes in-
cluded proteins associated with the inflammatory
response, defense response, and proteins involved
in the synthesis of the extracellular matrix.
Esson et al. also performed a microarray analysis
of blebs after glaucoma filtration surgery in Sprague
Dawley rats and found a significant treatment effect
in 923 genes.7 Their results confirmed the expres-
sion patterns of knownmediators of the bleb scarring
process, including transforming growth factor-b,
connective tissue growth factor, matrix metallopro-
teinases, and structural proteins like collagens.
In addition, Mahale et al. used the human RT2
Profiler polymerase chain reaction (PCR) array to
study the differential gene expression between se-
ven capsules of failed Ahmed glaucoma valves and
two control Tenon’s capsules.8 They found 39 genes
with more than two-fold differential gene expres-
sion in three or more of the capsules, including
CTGF, THBS1, SERPINE1, THBS2, COL3A1,
MMP3, and IL1A genes. Inflammation is a known
risk factor for scarring after glaucoma surgery,9
and Mahale et al. also found dysregulation of sev-
eral genes expressing inflammatory cytokines and
chemokines (CCL11, IL13, IL1A, IL1B, CXCR4).8
Their results are supported by the work of Chang
et al. who found increased mast cell numbers in
the conjunctival tissues of patients with previous
glaucoma surgery that might be associated with an
increased risk of conjunctival scarring10,11 and
previous findings that chronic treatment with eye-
drops resulted in an increase in inflammatory cells
and an increased chance of surgical failure.12,13
Conjunctival scarring is also critical following
Chlamydia trachomatis infection that leads to tri-
chiasis (inturned eyelids) and painful blindness in
trachoma. Burton et al. performed a microarray
Figure 1. Fibrosis forms part of the pathogenesis or failure of treatment of most blinding diseases worldwide such as glaucoma, trachoma, corneal fibrosis,
age-related macular degeneration, and proliferative vitreoretinopathy. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/wound
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analysis on 45 patients with trachomatous trichi-
asis (TT), as well as real-time quantitative PCR for
16 gene expression targets on 386 TT patients and
386 normal controls.14 They found that the gene
expression profile of TT patients was consistent
with squamous metaplasia (keratins, SPRR), pro-
inflammatory cytokine production (IL1b, CXCL5,
S100A7), and tissue remodeling (MMP7, MMP9,
MMP12, HAS3). Clinical inflammation was asso-
ciatedwith increasedS100A7, IL1B, IL17A, CXCL5,
CTGF, CEACAM5, MMP7, CD83 and reduced
SPARCL1 gene expression.15 Burton et al. also re-
ported an increased expression of the S100A7
(psoriasin) gene in patients with recurrent TT.16
Ocular cicatricial pemphigoid (OCP) is another
sight-threatening disease that is associated with
severe and chronic conjunctival fibrosis. Razzaque
et al. compared conjunctival fibroblasts from 10
OCP patients and 5 normal controls. They found an
increased expression ofm-CSF,17CTGF,18HSP47,19
andmacrophagemigration inhibitory factor (MIF)20
genes in OCP patients using real-time quantitative
PCR. Saw et al. also reported an increased expres-
sion of interleukin-1321 and tumor necrosis factor-
alpha22 in mucous membrane pemphigoid fibro-
blasts compared to normal human fibroblasts.
Corneal fibrosis is a leading cause of blindness
worldwide and can occur after corneal injury, sur-
gery, or secondary to infection (e.g., herpetic ker-
atitis) or inflammation (e.g., pterygium). Varela
et al. carried out a microarray analysis on rat cor-
neas after Excimer laser photorefractive kera-
tectomy and identified 73 genes with a three-fold
change in expression compared to untreated cor-
neas.23 These included genes that play an impor-
tant role in corneal wound healing, namely growth
factors, cell cycle regulators, transcription factors,
and metabolic pathway genes.
Using cDNA microarrays, Cao et al. also found
the expression of 37 genes to be upregulated and
that of 27 genes to be downregulatedmore than five-
fold in healing mouse corneas compared to nor-
Figure 2. The conjunctiva undergoes marked histopathological changes after glaucoma filtration surgery in (A) humans and (B) a rabbit model of conjunctival
fibrosis. There is increased cellularity and aSMA staining in fibrotic human and rabbit conjunctiva compared to nonfibrotic conjunctiva. Scale bar= 50lm. aSMA,
alpha smooth muscle actin. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/wound
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mal uninjured corneas.24 The upregulated genes
included ICAM-1, macrophage inflammatory pro-
teins, SOCS, IL-10 receptor, and galectin-7. Among
the downregulated genes were a gap junction pro-
tein (connexin-31), tight junction proteins (ZO1 and
occludin), and a key component in the TGFb sig-
naling pathway (Smad2).
Moreover, Saravanan et al. analyzed the dif-
ferential expression of glycosyltransferases in
healing mouse corneas using glycogene micro-
arrays.25 They found 11 enzymes to be upregu-
lated, namely glycosyltransferases, beta3GalT5,
T-synthase, GnTIVb, and 19 enzymes to be down-
regulated, namely GnTIII and sialyltransferases, in
healing mouse corneas compared to normal unin-
jured corneas.
Retinal fibrosis is the common pathophysiologi-
cal mechanism in blinding retinal diseases, such as
age-related macular degeneration (AMD), diabetic
retinopathy, and proliferative vitreoretinopathy
(PVR). Using an Affymetrix human genome mi-
croarray, Hollborn et al. studied differentially ex-
pressed genes between retinas of two PVR patients
and seven postmortem normal retinas.26 They
found upregulation of 80 genes, namely encoding
nuclear and cell cycle-related proteins, extracel-
lular secretory proteins, cytosolic signaling pro-
teins, and extracellular matrix proteins. The HGF
and heparin-binding EGF-like growth factor
genes were also expressed in PVR retinas, but not
in control retinas.
In addition, Asato et al. studied the gene ex-
pression profile of three eyes with PVR-epiretinal
membranes and two eyeswith secondary epiretinal
membranes.27 They found 1116 non-redundant
clusters representing individual genes expressed
in PVR-epiretinal membranes, and 799 clusters
representing the genes expressed in secondary
epiretinal membranes. Their results support that
PVR-epiretinal membranes represent an aberrant
form of the wound healing response in the retina,
with an increased expression of genes involved in
cell adhesion and proliferation.
There have been several genomic studies to date,
but most of them have been carried in animals or
small cohorts of patients (Table 1). Future research
is thus needed to validate these results in large
longitudinal human studies. One of the major
hurdles has been the lack of availability of human
tissues for biomarker research. Effective detailed
clinical phenotyping and biobanking of large co-
horts of patients will therefore be crucial to study
putative biomarkers in fibrotic eye diseases com-
pared to healthy controls. Another exciting pros-
pect in the future will be to use new advances in
genomics, namely next-generation whole genome
sequencing like RNA-Seq, to develop a customized
gene chip in ocular fibrosis.
Serum and tear biomarkers
As tissue biopsy can lead to scarring, serum and
tear biomarkers represent a less invasive alterna-
tive to tissue biopsy in fibrosis (Table 1). The en-
hanced liver fibrosis (ELF) test is a clinical-grade
serum test that could be used as a biomarker of
overall fibrosis in liver fibrosis28 and systemic
sclerosis.29 FibroMeters are blood tests that dis-
play a high overall diagnostic accuracy in staging
and quantification of liver fibrosis, and are useful
for patient follow-up.30 The serum levels of miR-
29a are also significantly associated with patients
with liver fibrosis,31 and hypertrophy and fibrosis
in patients with hypertrophic cardiomyopathy.32
For the anterior segment of the eye, Tezel et al.
used liquid chromatography and linear ion trap
mass spectrometry to compare the sera of 111 pa-
tients with primary open-angle glaucoma (POAG)
and 49 healthy controls.33 They found 106 proteins
to be increased in the glaucomatous sera and 63
proteins to be present in only the glaucomatous
sera. They validated their results and identified
four molecules (apoptosis-inducing factor, CREB-
binding protein, ephrin type-A receptor, huntingtin
protein) with higher serum enzyme-linked immu-
nosorbent assay titers in the POAG patients. Chong
et al. also determined the tear cytokine profile using
a multiplex bead assay in 61 glaucoma patients and
29 normal subjects, and found that the eyes at risk
of scarring in the early postoperative period had
significantly increased MCP-1 level.34
Serum biomarkers have been studied in
more detail for the posterior segment of the eye,
namely following laser-induced retinal injuries.
Dunmire et al. used liquid chromatography–tan-
demmass spectrometry and found 19 proteins to be
significantly increased in the sera of Rhesus ma-
caques after laser-induced retinal injury.35 Four
proteins (phosphoglycerate kinase 1, keratin 18,
Lewis alpha-3-fucosyltransferase, and ephrin re-
ceptor A2) showed significant differences at both
4hours and 1 day after laser injury, followed by a
decrease to baseline levels by the third day. Scott
et al. also identified four autoantigens in the sera
of rabbits after minimally invasive and grade II
laser-induced retinal injuries using liquid chro-
matography/tandemmass spectrometry.36 The four
candidate autoantigens were dihydropyrimidinase-
related protein 2, fructose-bisphosphate aldolase C,
chaperonin-containing T-complex polypeptide 1
subunit zeta, and pyruvate kinase isozyme.
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Table 1. Potential novel biomarkers in ocular fibrosis and wound healing
Biomarkers References Techniques Species and Tissues Results
Tissue genomics Popp et al.6 Microarray Rabbit conjunctiva and Tenon’s
capsules after GFS
315 genes, namely encoding serum amyloid A-3
protein, IL-1 beta, alpha-1-acid glycoprotein,
cathepsin K, MMP-9, neutrophil granules matrix
glycoprotein SGP28, ceruloplasmin, lumican, lyso-
zyme C, and fibronectin
Esson et al.7 Microarray Rat blebs after GFS 923 genes, namely encoding TGFb, CTGF, FGF, IGF,
matrix metalloproteinases, collagens, vimentin,
and fibronectin
Mahale et al.8 RT2 Profiler PCR Array 7 human Tenon’s capsules of
failed Ahmed valves
39 genes, including CTGF, THBS1, SERPINE1, THBS2,
COL3A1, MMP3, and IL1A genes
Varela et al.23 Microarray Rat corneas after Excimer PRK 73 genes, including growth factors (VEGF, FGF, IGF-I),
proteases (PAI-1, PAI-2A), and protease inhibitors
(TIMP-2, TIMP-3)
Burton et al.14,15 Microarray
Real-time quantitative PCR
45 trachomatous trichiasis
patients
386 trachomatous trichiasis
patients
Squamous metaplasia (keratins, SPRR), proinflam-
matory cytokine production (IL1b, CXCL5, S100A7),
and tissue remodeling (MMP7, MMP9, MMP12,
and HAS3)
Razzaque et al.17–20 Real-time quantitative PCR 10 patients with ocular cicatricial
pemphigoid
Upregulated m-CSF, CTGF, HSP47, and MIF genes
Cao et al.24 cDNA microarrays Healing mouse corneas 37 genes upregulated and 27 genes downregulated,
namely encoding ICAM-1, macrophage inflamma-
tory proteins, SOCS, IL-10 receptor, galectin-7,
connexin-31, ZO1 and occludin, and Smad2
Saravanan et al.25 Glycogene microarrays Healing mouse corneas 11 enzymes upregulated and 19 enzymes down-
regulated, including glycosyltransferases, beta3-
GalT5, T-synthase, GnTIVb, GnTIII, and
sialyltransferases
Hollborn et al.26 Affymetrix human genome
microarray
2 human retinas of PVR patients 80 genes upregulated, namely encoding nuclear and
cell cycle related, extracellular secretory, cytosolic
signaling, and extracellular matrix proteins, HGF,
and HB-EGF
Asato et al.27 PCR-amplified cDNA library 3 human eyes with PVR-epiretinal
membranes
1116 gene clusters, namely related to metabolism,
cell adhesion, cytoskeleton, and signaling
Serum and tear
biomarkers
Tezel et al.33 Linear ion trap mass spectrometry 111 patients with POAG 63 proteins, including AIF, CREB-binding protein,
ephrin type-A receptor, and huntingtin protein
Chong et al.34 Tear cytokine profile using
multiplex bead assay
61 glaucoma patients Increased MCP-1 level
Dunmire et al.35 Liquid chromatography–
Mass spectrometry
Rhesus macaques sera after
laser-induced retinal injury
19 proteins, including phosphoglycerate kinase 1,
keratin 18, Lewis alpha-3-fucosyltransferase, and
ephrin receptor A2
Scott et al.36 Liquid chromatography–
Mass spectrometry
Rabbit sera after laser-induced
retinal injury
4 candidate autoantigens, namely
dihydropyrimidinase-related protein 2, fructose-
bisphosphate aldolase C, chaperonin-containing T-
complex polypeptide 1 subunit zeta, and pyruvate
kinase isozyme
Kierny et al.37 Mass spectrometry, phage-display Rabbit sera after laser-induced
retinal injury
Antibodies against 4 peptides derived from putative
biomarkers; GBB5 retinal protein
Proteomics Sacca` et al.42 Antibody microarray method Aqueous humour of 14 POAG
patients
13 proteins, including apolipoprotein B, apolipopro-
tein E, vasodilator-stimulated phosphoprotein,
heat shock 60 kDa protein, heat shock 90 kDa
protein, myogenin, myogenic factor 3, myotrophin,
ankyrin, ubiquitin fusion degradation 1-like, phos-
pholipase C beta 1, phospholipase C gamma 1,
and albumin
Anshu et al.43 Liquid chromatography–
Mass spectrometry
Aqueous humour of 11 patients
with glaucoma tube implants
13 proteins, including gelsolin, plasminogen, angio-
tensinogen, apolipoprotein A-II, beta-2-
microglobulin, dickkopf-3, pigment epithelium-
derived factor, RIG-like 7–1, afamin, fibronectin 1,
apolipoprotein A-I, activated complement C4 pro-
tein, and prothrombin
Rosenfeld et al.44 Liquid chromatography–
Mass spectrometry
Aqueous humour of 20 patients
with glaucoma implants
718 proteins, splice variants or isoforms
(continued)
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In addition, Kierny et al. generated recombinant
antibodies against putative biomarkers of retinal
injury in rabbit sera following laser-induced retinal
injury.37 They generated single-chain variable
fragment antibodies against four peptides derived
from putative biomarkers of laser-induced retinal
injury using phage display. One antibody against
the retinal protein, guanine nucleotide-binding
protein beta 5 (GBB5), was carried further to
demonstrate a method to characterize antibodies
generated from peptide fragments identified by
mass spectrometry of serum samples.
Proteomics
Proteomics is gaining increasing interest in the
field of eye research due to recent advances in
protein chemistry, mass spectrometry, and bioin-
formatics38 (Table 1). Several groups are develop-
ing potential proteomic biomarkers in idiopathic
pulmonary fibrosis39 and liver fibrosis.40,41 In the
Table 1. (Continued)
Biomarkers References Techniques Species and Tissues Results
Mandal et al.45 Liquid chromatography–
Mass spectrometry
Rabbit detached retina 18 proteins, including vimentin, tubulin b-2C, frag-
ments of a-enolase, fructose-bisphosphate, aldol-
ase A, ATP synthase subunit b, mitochondrial
creatine kinase, N-terminal fragments of albumin,
prohibitin, and transducin-b1
Yu et al.46 Mass spectrometry 24 human vitreous samples from
RRD patients with PVR
Upregulated alpha2-HS-glycoprotein, alpha1B-
glycoprotein, complement components, and he-
mopexin; Downregulated opticin precursors and
actin family members
Yu et al.47 Liquid chromatography–
Mass spectrometry
24 PVR patients with RRD Upregulated transferrin, albumin precursor, alpha2-
HS-glycoprotein, alpha1B-glycoprotein, serpins
family, and complement components; Downregu-
lated tubulin, pyruvate kinase 3, enolase, and
GAPDH
Metabolomics Karamichos et al.52 Mass spectrometry Human keratoconus cell lines Elevated lactate levels, lactate/malate, and lactate/
pyruvate ratios; Reduced arginine levels and
glutathione/oxidized glutathione ratio
Li et al.54 Mass spectrometry 17 human vitreous samples from
RRD and PVR patients
31 metabolites, including L-carnitine, urea, phenyl-
pyruvate, cyromazine, hypoxanthine, citrate, gly-
cerate, ascorbate, and 2-Oxoglutarate
Osborn et al.55 Liquid chromatography–
Mass spectrometry
26 patients with neovascular AMD
and fibrovascular tissue
94 metabolic features, namely acetylphenylalanine,
glycocholic acid, vitamin D-related metabolites,
phenylalanine, tyrosine, glutamine, and aspartate
Agudo-Barriuso
et al.56
Mass spectrometry Rat optic nerve injury 27 metabolites (between control and 14 days) and 36
metabolites (between 24 h and 14 days), linked to
translation, oxidative stress, glucose and tricar-
boxylic acid cycle and apoptosis
Clinical
phenotyping
Kon et al.57
Asaria et al.58
Univariate and multivariate
logistic regression analysis
140 patients having a primary
vitrectomy for rhegmatogenous
retinal detachment
Risk factors for PVR: Preoperative PVR, aphakia, and
high vitreous protein levels
Rajak et al.59 Logistic regression analysis 1300 patients with trachomatous
trichiasis in Ethiopia
Risk factors for recurrence: Preoperative major
trachomatous trichiasis (>5 trichiatic lashes),
preoperative entropic lashes compared to misdir-
ected/metaplastic lashes, and age over 40 years
Noninvasive
Imaging
Farid et al.65 Second-harmonic generation
confocal microscopy
Rabbit corneal fibrosis after
excimer laser surface ablation
High cell density and alignment of intracellular actin
filaments with collagen fiber bundles
Teng et al.67 Multiphoton imaging and
second-harmonic generation
microscopy
1 patient with penetrating corneal
injury
Irregularly arranged collagen fibers and lack of
collagen fibers within the corneal wound
Kawana et al.70 Anterior segment OCT 38 filtering blebs in 31 patients Successful blebs showed a large internal fluid-filled
cavity, an extensive hyporeflective area, and
thicker bleb walls
Singh et al.71,72 Anterior segment OCT 78 filtering blebs in 55 patients Successful blebs displayed thickening of the bleb
wall
Siriwardena et al.73 Laser flare meter 131 trabeculectomy patients Increased anterior chamber flare and inflammation
Wolff et al.75 Spectral domain OCT 15 eyes with neovascular AMD Branching retinal tubulation network emanating from
a fibrovascular scar
Coscas et al.76 Spectral domain OCT 38 patients with fibrovascular PED Homogeneous hyperreflectivity consistent with
fibrous tissue
GFS, glaucoma filtration surgery; PCR, polymerase chain reaction; PVR, proliferative vitreoretinopathy; POAG, primary open-angle glaucoma; RRD,
rhegmatogenous retinal detachment; AMD, age-related macular degeneration; OCT, optical coherence tomography; PED, pigment epithelial detachment.
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eye, Sacca` et al. compared the aqueous humour
proteome of 14 POAG patients to that of normal
controls using the antibody microarray method.42
They found the levels of 13 proteins to be signifi-
cantly increased in the aqueous humour of POAG
patients. These proteins are involved in inflam-
mation, delivery of cholesterol to cells, muscle cell
differentiation, stress response, and signal trans-
duction, and might reflect the damage occurring to
the trabecular meshwork and to the anterior
chamber endothelia in glaucoma.
Anshu et al. also identified 13 proteins to be sig-
nificantly higher in the aqueous humour of 11 pa-
tients with a glaucoma tube implant using liquid
chromatography–mass spectrometry.43 These pro-
teins play a role in oxidative stress, apoptosis, in-
flammation, and immunity, and their presence in
the aqueous humour suggests that glaucoma tube
implants cause either a breach in the blood–aqueous
barrier or chronic trauma, increasing the influx of
oxidative, apoptotic, and inflammatory proteins. In
addition, Rosenfeld et al. studied the aqueous hu-
mour of 20 patients with different glaucoma opera-
tions.44 They found the aqueous humour protein
concentrations to be ten-fold in the Ahmed and
Baerveldt eyes and five-fold in the trabeculectomy
and Ex-PRESS eyes. They also identified 718 un-
ique proteins, splice variants or isoforms using liq-
uid chromatography–tandem mass spectrometry.
Retinal detachment leads to cellular remodeling
of the retina.Mandal et al. reported that 18 proteins
were differentially expressed between detached
rabbit retina and controls using liquid chromatog-
raphy–tandem mass spectrometry.45 The proteins
identified were involved in a wide range of pro-
cesses, including cell metabolism, cell structure,
mitochondrial function, and phototransduction, and
might play an important role in thewound response
of the retina after its detachment and its subsequent
ability to recover following surgical reattachment.
Using sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and reverse-phase liquid chro-
matography–tandem mass spectrometry, Yu et al.
also found 48 overlapping proteins in the vitreous
of 24 patients with rhegmatogenous retinal de-
tachment (RRD) and PVR.46 The authors used
GeneGoMetaCore (Version 6.6; GeneGo, Carlsbad,
CA) for the enrichment flow analysis. They found
inflammation to be an important GeneGo network
and identified the complement and coagulation
cascade as the essential pathway. Yu et al. also
carried out a vitreous proteomic analysis in 24 PVR
patients with RRD using two-dimensional nano
liquid chromatography coupled with tandem mass
spectrometry.47 They identified 102 PVR-specific
proteins and proposed that kininogen 1 could be-
come a potential candidate biomarker as it was
specifically detected in both the vitreous and cor-
responding serum samples.
Metabolomics
Metabolomics is a relatively new technology that
measures the set of metabolites that make up the
metabolome of a cell or tissue,48 and there has been
growing interest in using metabolomics to identify
clinically relevant biomarkers49 (Table 1). Several
metabolic products have been reported as bio-
markers of fibrosis in nonalcoholic fatty liver dis-
ease.50 Alterations in metabolic pathways have also
been reported in idiopathic pulmonary fibrosis and
measurement of these metabolites could be used as
future diagnostic and prognostic biomarkers.51
Keratoconus is a corneal ectasia that is associated
with corneal scarring, and altered cellular metabo-
lism has been linked to promoting the fibrotic phe-
notype and scarring in the cornea. Karamichos et al.
identified that several of the metabolic pathways
that were significantly different between human
keratoconus cells and human corneal keratocytes
were related to oxidative stress, and that human
keratoconus cells expressed elevated lactate levels,
lactate/malate and lactate/pyruvate ratios, and re-
duced arginine levels and glutathione/oxidized glu-
tathione ratio.52
PVR is the major cause of failure of retinal de-
tachment surgery and is caused by contraction of
fibrotic membranes on the epiretinal surface of the
neurosensory retina.53 Using reversed-phase liquid
chromatography–quadrupole time-of-flight mass
spectrometry, Li et al. identified 31 metabolites as
potential biomarkers in 17 vitreous samples of PVR
patients.54 Inflammation, proliferation, and energy
consumption were the three major disturbed bio-
logical processes involved in PVR development.
Osborn et al. also performed a metabolome-wide
association study of 26 patients with neovascular
AMD and fibrovascular tissue using liquid chroma-
tography and Fourier transform mass spectrome-
try.55 They found 94 unique metabolic features to be
significantly different between patients with neo-
vascular AMD and fibrovascular tissue compared to
healthy controls.
In addition, Agudo-Barriuso et al. identified 27
metabolites to discriminate between control and
14 days after rat optic nerve injury, using gas
chromatography/mass spectrometry and liquid
chromatography/mass spectrometry techniques.56
Enrichment analysis showed alterations in the
amino acid, carbohydrate, and lipid metabolism
that were further linked to translation, oxidative
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stress, energy (glucose and tricarboxylic acid cy-
cle), and apoptosis through ceramide pathways.
Clinical phenotyping
Clinical phenotyping is another critical aspect of
personalized medicine and several groups have
studied potential clinical models to predict the risk
of scarring and fibrosis in the eye (Fig. 3 and Ta-
ble 1). Kon et al. carried out a univariate and mul-
tivariate logistic regression analysis on 140 patients
with RRD.57 They found that the significant risk
factors associated with the development of PVR
were preoperative PVR, aphakia, and high vitreous
protein levels. The authors also constructed two
statistical models (clinical factors only and clinical
factors combined with vitreous protein level) to
predict the probability of developing postoperative
PVR and to identify the high-risk patients that
might benefit from pharmacological antifibrotic
therapies.57,58
Moreover, trachoma is the most common infec-
tious cause of blindness worldwide and causes tri-
chiasis, leading to conjunctival scarring and visual
loss. Lid rotation surgery is the mainstay of treat-
ment for TT, but the risk of recurrence is high.
Rajak et al. carried out a 2-year follow-up study of
Figure 3. Detailed clinical phenotyping of patients alongside effective biobanking of tissues from large patient cohorts will be critical for future biomarker research
in ocular fibrosis. (A) Glaucoma blebs are graded with respect to area [scale 1–5], height [scale 1–4], and vascularity [scale 1–5]. (B) The severity of proliferative
vitreoretinopathy is graded as Grade A [vitreous haze and RPE cells in vitreous], Grade B [wrinkling of the edges of the retinal tear or inner retinal surface], or Grade
C [formation of retinal membranes]. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/wound
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1300 patients with TT in Ethiopia.59 The authors
found that recurrence was associated with specific
clinical features such as major TT preoperatively
(>5 trichiatic lashes), preoperative entropic lashes
compared to misdirected/metaplastic lashes, and
age over 40 years.
Noninvasive imaging
High-resolution real-time in vivo imaging rep-
resents a promising new technique to help stratify
patients in fibrosis and wound healing (Fig. 4 and
Table 1). Positron Emission Tomography (PET) is
a functional noninvasive imaging technique,
whereby the concentration of the biologically ac-
tive tracer, fluorodeoxyglucose, corresponds to
tissue metabolic activity. Several research groups
have studied the use of PET scans to monitor id-
iopathic lung fibrosis,60 retroperitoneal fibrosis,61
andmyelofibrosis.62 FibroScan is also anultrasound-
based transient elastography technique and is
currently the most reliable noninvasive method to
assess liver stiffness and fibrosis, as an alterna-
tive to liver biopsy.63,64
In the eye, several groups have shown that high-
resolution, high-contrast second-harmonic gener-
ation imaging provides a sensitive means to detect
corneal fibrosis after excimer laser surface ablation
and corneal injury.65–67 The corneal wound was
associated with high cell density and alignment of
intracellular actin filaments with collagen fiber
bundles,65 and irregularly arranged collagen fi-
bers.67 The authors thus suggested that high-
resolution in vivo imaging could be used in the fu-
ture to assess the effects of antifibrotic therapy on
corneal wound healing after refractive surgery or
corneal injury.
Simple image grading, particularly of redness
indicating inflammation, is a very good indicator of
impending failure of glaucoma filtration surgery.68
Other research groups have also investigated the
use of anterior segment optical coherence tomog-
raphy (AS-OCT) to predict the surgical failure and
scarring after glaucoma drainage surgery.69–72 AS-
OCT was used to assess different bleb character-
istics, including total bleb height, bleb cavity, bleb
wall thickness, scleral flap thickness, and patency
Figure 4. High-resolution noninvasive in vivo imaging represents a promising new technique to help stratify patients with different fibrotic eye diseases: (A)
SHG imaging; (B) Laser flare meter; (C) Simple image grading (vascularity); (D) AS-OCT; (E) SD-OCT. SHG, second-harmonic generation; AS-OCT, anterior
segment optical coherence tomography; SD-OCT, spectral domain optical coherence tomography. To see this illustration in color, the reader is referred to the
web version of this article at www.liebertpub.com/wound
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of the internal ostium. Features of suc-
cessful blebs were thickening of the bleb
wall,70,71 a large internal fluid-filled cav-
ity, and an extensive hyporeflective area
compared to unsuccessful blebs.70
In addition, recent cataract surgery is
a risk factor for failure of glaucoma fil-
tration surgery. Using the Kowa FM-500
laser flare meter that measures the level
of aqueous humour protein noninva-
sively in 131 patients undergoing trabe-
culectomy and 148 patients undergoing
cataract surgery, Siriwardena et al. found
that the anterior chamber flare was more
prolonged after cataract surgery than af-
ter trabeculectomy.73 The release of lens
crystallins and lens epithelial cells might
upregulate the production of fibrogenic
cytokines in the aqueous humour of
patients after cataract surgery.74 The
authors thus suggested that anterior
chamber flare could be used as a surrogate bio-
marker of anterior chamber inflammation and help
guide the timing of trabeculectomy in relation to
cataract surgery.
Different research groups have also studied
spectral-domain optical coherence tomography
(SD-OCT) as a potential future tool to diagnose and
follow-up patients with fibrovascular retinal dis-
eases. Using SD-OCT, Wolff et al. found a branch-
ing retinal tubulation network emanating from a
fibrovascular scar among 15 eyes of patients with
neovascular AMD.75 Coscas et al. also studied 38
patients with fibrovascular pigment epithelial de-
tachment (PED) and identified a homogeneous
hyperreflectivity pattern consistent with fibrous
tissue using SD-OCT.76
SUMMARY
There have been significant advances in the
use of genomics, proteomics, metabolomics, clin-
ical phenotyping, and high-resolution in vivo
imaging techniques to help identify and stratify
the groups of patients at risk of scarring in dif-
ferent fibrotic eye diseases (Table 1). However,
most of the studies to date have been carried out
in animals or small cohorts of patients, and future
research is thus needed to validate these results
in large longitudinal human studies. Effective
detailed clinical phenotyping, including high-
resolution imaging and biobanking of tissues
from large patient cohorts, will also be crucial to
compare putative biomarkers in ocular fibrosis to
healthy controls.
As tissue biopsy can itself induce scarring in the
eye, there has been growing interest in developing
less invasive biomarkers such as serum or tear
biomarkers and high-resolution in vivo imaging
techniques. Another exciting future prospect will
be to use new advances in genotyping, namely
next-generation whole genome sequencing like
RNA-Seq, to develop a customized gene chip in
ocular fibrosis. We believe that a strong collabo-
ration between academics, pharmaceutical, and
biotech companies will also be critical for suc-
cessful translation of these biomarkers to benefit
patient care. The ultimate goal in the future will
be to apply diagnostic and therapeutic biomark-
ers and to develop a more stratified approach in
antifibrotic ocular therapeutics and personalized
visual health.
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TAKE-HOME MESSAGES
1. There is a large unmet clinical need for reliable biomarkers in ocular and
systemic fibrosis.
2. There have been significant advances in genomics, proteomics, meta-
bolomics, and high-resolution imaging to help stratify the risk of scarring
in fibrotic eye diseases.
3. Future research is needed to validate these results in large longitudinal
human studies.
4. Effective detailed clinical phenotyping, including imaging and biobanking
of tissues from large patient cohorts, will be critical to compare putative
biomarkers in ocular fibrosis to healthy controls.
5. Successful translation of these biomarkers will ultimately require a
strong collaboration between academics, pharmaceutical, and biotech
companies.
6. An exciting future prospect will be to use next-generation whole ge-
nome sequencing, like RNA-Seq, to develop a customized gene chip in
ocular fibrosis.
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Abbreviations and Acronyms
AIF ¼ apoptosis-inducing factor
AMD ¼ age-related macular degeneration
AS-OCT ¼ anterior segment OCT
CCL11 ¼ chemokine (C-C motif ) ligand 11
CEACAM5 ¼ carcinoembryonic antigen-related
cell adhesion molecule 5
COL3A1 ¼ collagen type III alpha 1
CREB ¼ cyclic AMP-responsive element-
binding protein
CTGF ¼ connective tissue growth factor
CXCL5 ¼ chemokine (C-X-C motif ) ligand 5
CXCR4 ¼ chemokine (C-X-C motif ) receptor 4
DNA ¼ deoxyribonucleic acid
EGF ¼ epidermal growth factor
ELF ¼ enhanced liver fibrosis
ERM ¼ epiretinal membrane
FGF ¼ fibroblast growth factor
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
GBB5 ¼ guanine nucleotide-binding protein
beta 5
GFS ¼ glaucoma filtration surgery
HAS3 ¼ hyaluronan synthase 3
HGF ¼ hepatocyte growth factor
HSP47 ¼ heat shock protein 47
ICAM ¼ intercellular adhesion molecule
IGF ¼ insulin-like growth factor
IL ¼ interleukin
MCP-1 ¼ monocyte chemoattractant
protein 1
m-CSF ¼ macrophage colony-stimulating
factor
MIF ¼ migration inhibitory factor
MMP ¼ matrix metalloproteinase
OCP ¼ ocular cicatricial pemphigoid
OCT ¼ optical coherence tomography
PAI ¼ plasminogen activator inhibitor
PCR ¼ polymerase chain reaction
PED ¼ pigment epithelial detachment
PET ¼ positron emission tomography
POAG ¼ primary open-angle glaucoma
PVR ¼ proliferative vitreoretinopathy
RNA-Seq ¼ RNA sequencing
RRD ¼ rhegmatogenous retinal
detachment
S100A7 ¼ S100 calcium-binding protein A7
SAGE ¼ serial analysis of gene expression
SD-OCT ¼ spectral domain OCT
SDS-PAGE ¼ sodium dodecyl sulfate–
polyacrylamide gel electrophoresis
SHG ¼ second-harmonic generation
SOCS ¼ suppressor of cytokine signaling
SPARCL1 ¼ secreted protein, acidic and rich
in cysteine-like 1
TGFb ¼ transforming growth factor beta
THBS1 ¼ thrombospondin 1
THBS2 ¼ thrombospondin 2
TIMP ¼ tissue inhibitor of metalloproteinase
TT ¼ trachomatous trichiasis
VEGF ¼ vascular endothelial growth factor
aSMA ¼ alpha smooth muscle actin
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